Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Recordati S.p.A., an established international pharmaceutical group also known simply as Recordati, traces its origins back to its founding in 1926. Headquartered in Luxembourg, the company maintains a significant global footprint, with key operational centres including Italy and a presence in over 150 countries.
As a leader in pharmaceutical preparation manufacturing, Recordati excels in the research, development, manufacturing, and marketing of innovative healthcare solutions. Its core business areas encompass speciality and primary care products, alongside a dedicated focus on providing essential therapies for rare diseases, aiming to improve patient well-being worldwide.
+37 vs industry average
RECORDATI’s score of 79 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
RECORDATI, a Pharmaceutical Preparation Manufacturing company headquartered in Luxembourg, reported total emissions of approximately 308.2 million kg CO2e in 2025. This includes about 36.6 million kg CO2e from Scope 1 emissions, approximately 1.3 million kg CO2e from Scope 2 (market-based), and around 270.3 million kg CO2e from Scope 3 emissions.
In 2024, the company's total emissions were approximately 346.5 million kg CO2e, comprising about 37.3 million kg CO2e from Scope 1, 1.7 million kg CO2e from Scope 2 (market-based), and 307.5 million kg CO2e from Scope 3.
RECORDATI has set several climate commitments. The company aims to reduce its Scope 1 emissions by 30% from a 2021 baseline by 2030 and its Scope 2 emissions by 30% from a 2021 baseline by 2030. Additionally, the company has a broader goal of achieving a 20% reduction in combined Scope 1 and Scope 2 emissions by 2030 from a 2022 baseline.
RECORDATI has also committed to purchasing 100% renewable electricity for its Group production and packaging sites and annexed offices by 2025.
Through its corporate family relationship, RECORDATI inherits Science Based Targets initiative (SBTi) commitments from its ultimate parent, Recordati Industria Chimica e Farmaceutica S.p.A. REC Corporation, an SME, commits to reducing Scope 1 and Scope 2 GHG emissions by 42% by 2030 from a 2023 base year, consistent with a 1.5°C warming trajectory. The company also commits to measuring and reducing its Scope 3 emissions.
2030
42% reduction in Scope 2
2030
42% reduction in Scope 1
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about RECORDATI’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more